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Dong Jin Kim1, Jun Hyun Lee2 and Wook Kim1*Abstract
Adrenal metastasis following gastrectomy for gastric cancer is often encountered as part of advanced systemic
dissemination, which is usually unresectable. Thus, there are very few published case reports describing
metastasectomy for adrenal metastasis from gastric cancer. Herein we present our experience in treating two
patients diagnosed and treated for adrenal metastasis 6 years following initial surgery for advanced gastric cancer
(pT2bN1M0 and pT2bN0M0, respectively, according to the classification system set forth in the sixth edition of
The TNM Classification of Malignant Tumours by the International Union against Cancer). They underwent successful
en bloc R0 resections, followed by systemic chemotherapy with close postoperative follow-up for another
recurrence, and have remained alive without recurrence for 1 year. These results suggest that active surgical
treatment for resectable metastatic gastric cancer in the adrenal glands has an important role in prolonging survival
in selected patients.
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Common recurrence patterns following curative resec-
tion for advanced gastric cancer (AGC) are peritoneal
dissemination and hematogenous metastasis. The liver is
the main focus among extraperitoneal metastases, and
the lung is the secondary focus [1,2]. Although some
autopsy studies have shown that 16% to 18% of patients
with gastric cancer developed adrenal metastases [3,4],
most occurred in connection with multiple synchronous
metastases to other sites [5]. Herein we report the cases
of two patients with late-onset single adrenal metastases
6 years after gastrectomy for AGC who underwent suc-
cessful curative resection.Case presentations
Case 1
A 51-year-old man visited our hospital for a regular
postoperative follow-up examination for gastric cancer
in April 2012. He had undergone a total gastrectomy for* Correspondence: kimwook@catholic.ac.kr
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reproduction in any medium, provided the orAGC on the cardia in September 2006 (pT2bN1M0,
stage II, according to the classification system set forth
in the sixth edition of The TNM Classification of
Malignant Tumours by the International Union against
Cancer (UICC) [6]). At that time, the histological
examination revealed a poorly differentiated tubular
adenocarcinoma that had infiltrated the subserosal layer.
Thirty-five lymph nodes were retrieved, and one was
metastatic. After an R0 resection, the patient received
six cycles of cisplatin and 5-fluorouracil (5-FU) combi-
nation chemotherapy until March 2007. He was followed
up regularly with tumor markers, abdominal computed
tomography (CT) scans and positron emission tomo-
graphy (PET)-CT every 6 months for 2 years and then
annually thereafter.
The patient had no symptoms or abnormal findings
suggesting recurrence until 5 years postoperatively, in
September 2011. An abdominal CT scan showed an
isolated left adrenal mass, 3 cm in size, with inhomo-
geneous enhancement, which was suspected to be a
relapse of the disease or an adrenal incidentaloma
(Figure 1A). He was recommended for a follow-up
examination because tumor markers were within normal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 Follow-up computed tomography and positron emission tomography–computed tomography scans of patient 1 obtained in
September 2011 show a 3-cm left adrenal mass (asterisk). (A) Computed tomography shows accidentally detected left adreanal mass.
(B) PET-CT shows significant FDG uptake area correlated with enlarged left adenal mass.
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(FDG) uptake visible on the PET scan (Figure 1B). Six
months later a CT scan showed that the preexisting
adrenal mass had increased in size (up to 6 cm), and
PET-CT scans showed a more definite hypermetabolic
focus (Figure 2). A CT-guided biopsy of the tumor was
performed for histological confirmation, which revealed
a poorly differentiated adenocarcinoma compatible with
metastasis from gastric cancer (Figure 3A). Following
sufficient exploration for surgical resection and other
alternative treatments, surgical resection was planned
with the patient’s informed consent.
In the patient’s second operation, 6 years after initial
operation, the left adrenal tumor was found to have
extended to the adjacent organs: to the distal pancreas
anteriorly, to the renal capsule inferiorly and to the dia-
phragm superiorly. An en bloc resection, including the
left adrenal gland, kidney, a portion of the diaphragm,
distal pancreas and spleen, was performed (Figure 3B).
Histopathological examination revealed a poorly diffe-
rentiated metastatic adenocarcinoma invading the renal
capsule and distal pancreas. Other than the main tumor,
we detected three metastatic lymph nodes among a total
of eight retrieved lymph nodes in the paraaortic region.
The patient’s postoperative course was uneventful,
and he was discharged on postoperative day 13. HeFigure 2 Follow-up computed tomography and positron emission tom
March 2012 show an increase in the size of the left adrenal mass. (A)
increased. (B) PET-CT shows interval increased FDG hot uptake area.subsequently received eight cycles of second-line chemo-
therapy with 120 mg/day S-1 (TS-1; Taiho Pharma-
ceutical, Tokyo, Japan). During the 13-month follow-up
period, there was no evidence of cancer recurrence
based on CT findings and tumor markers.
Case 2
A 45-year-old woman underwent distal gastrectomy for
AGC at our hospital in July 2006 (pT2bN0M0, stage IB,
according to the UICC classification system [6]). A
histological examination of the primary gastric cancer
lesion revealed a signet ring cell carcinoma that had
infiltrated the subserosal layer. There was no lymph
node metastasis in any of the 44 retrieved nodes, and
the proximal resected margin was 2.0 cm. The patient
remained well until 1 year after surgery, when recurrent
remnant gastric cancer invading the distal pancreas was
detected during a follow-up evaluation. After no other
metastasis was identified, a complete, total gastrectomy
with distal pancreaticosplenectomy was performed in
July 2007. Postoperative adjuvant combination chemo-
therapy included six cycles of 5-FU and cisplatin. She
remained well for 2 years following her second operation
until she experienced mild swallowing difficulty. A CT
scan and barium swallowing series showed a recurrent
mass around the jejunojejunostomy site that compressedography–computed tomography scans of patient 1 obtained in
Computed tomography image shows left adrenal mass interval
Figure 3 Histological tissue specimen and photograph of tumor showing poorly differentiated adenocarcinoma in case 1. (A) We
evaluated this computed tomography–guided biopsy specimen histologically (hematoxylin and eosin stain; original magnification, ×400).
(B) Photograph of the resected specimen from patient 1 shows a 6-cm adrenal mass invading the pancreas and the renal parenchyma.
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third operation was performed in July 2009. En bloc re-
section of the recurrent tumor, including the Roux limb,
was carried out, and a repeat esophagojejunostomy with
jejunojejunostomy was performed. She refused posto-
perative adjuvant chemotherapy and remained well for
3 years. However, a 3-cm left adrenal mass found on a
CT scan showed intense FDG uptake on PET-CT scans
(Figure 4). In this patient, sufficient clinical information
was available for surgical resection and other alternative
treatments, so surgical resection was planned with the
patient’s informed consent. A fourth operation was
performed in May 2012, including a left nephroa-
drenalelctomy, transverse colectomy and resection of the
Roux limb because of direct invasion of the adrenal
tumor into the renal capsule and adjacent jejunal mesen-
tery and mesocolon (Figure 5A). A histopathological
examination revealed a 6 × 3–cm adrenal tumor with
metastatic signet ring cell carcinoma, which is the same
histologic finding as that of primary and recurrent le-
sions (Figure 5B). The regional lymph nodes, including
jejunal mesentery (0 of 13), transverse mesocolon (0
of 1) and renal parenchyma were free from metastasis or
direct tumor invasion. The patient’s postoperative course
was uneventful, and she was discharged on postoperativeFigure 4 Computed tomography and positron emission tomography–
2012 show a 3-cm hypermetabolic left adrenal mass (asterisk). (A) Co
(B) PET-CT shows FDG hot uptake at corresponding area.day 10 without any complications. She received second-
line chemotherapy with seven cycles of 100 mg/day S-1.
During the 12-month follow-up period, no definite evi-
dence of tumor recurrence was found.
Discussion
Adrenal metastasis most commonly develops from lung
cancer, renal cell carcinoma, gastric cancer or esophageal
cancer [7,8]. Although some studies have shown less
than 10% adrenal metastasis in patients with gastric
cancer [9,10], recent autopsy and clinical studies have
revealed 16% to 18% adrenal metastasis in patients with
gastric cancer [3,4]. There are only a few treatment op-
tions available when adrenal metastasis develops, be-
cause the prognosis is poor when a local recurrence or
distant metastasis develops in a patient with gastric can-
cer [2]. If a solitary adrenal metastasis develops without
any other metastatic foci, surgical resection can be
applied to achieve cure. However, a solitary adrenal me-
tastasis is a very rare manifestation in a patient with
gastric cancer. In addition, our patients presented with
unusual clinical courses.
The role of surgical treatment for adrenal metastases
is still evolving, but several authors have advocated re-
section of adrenal metastases with curative intent incomputed tomography scans of patient 2 obtained in March
mputed tomography shows well circumscribed left adrenal mass.
Figure 5 Photograph and histological tissue specimen of resected tumor from patient 2 shows a 6 × 3–cm adrenal mass without
definite direct invasion into the renal parenchyma. (A) Photograph of the resected tumor. (B) Histological evaluation revealed a signet ring
cell carcinoma, which had the same histology as the primary lesion (hematoxylin and eosin stain; original magnification, ×400).
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disease exists. Although adrenalectomy for metastatic
gastric cancer has not been widely performed, surgical
resection has been adopted in many more cases, par-
ticularly in cases of lung cancer and renal cell carcinoma
[11,12]. In general, adrenalectomy for a metastatic
tumors is associated with a poor prognosis: The overall
5-year survival rate is 13% to 29%, and the median
survival time is 13 to 28 months [12,13]. However, only
surgical resection can cure a solitary adrenal metastasis.
Actually, compared with patients who undergo nonsur-
gical treatment for adrenal metastasis, surgically treated
patients have better survival [12,14]. In particular, an
adrenalectomy helps to prolong survival in patients with
a disease-free interval of more than 6 months and com-
pletely resectable metastatic foci. If a solitary metastatic
lesion is found within a sufficient period of time from
the initial operation, an adrenalectomy will be more ef-
fective. Whether induction chemotherapy is necessary
depends on tumor size and resectability.
Only three case reports have been published regarding
long-term survival following curative resection for soli-
tary adrenal metastasis in gastric cancer [5,15,16]. In
the absence of a randomized clinical trial or a large
case–control series, any patients who achieve long-term,
disease-free survival can be assumed to have derived a
clinically significant benefit.
It is not be necessary to perform a preoperative biopsy
when solitary adrenal metastasis is highly suspected on
the basis of imaging studies and clinical situations. We
did not seek preoperative histologic confirmation in
patient 2.
Both of our cases were of late onset (6 years following
gastrectomy) and involved solitary metastases to the
adrenal gland. In patient 2, two additional operations
were performed for remnant gastric cancer and a jejuno-
jejunostomy site recurrence. To be exact, the tumor in
this patient may not have been a late-onset adrenal
metastasis, but a missed cancer lesion. However, she hadnearly a 3-year relapse-free period without evidence of a
remnant cancer lesion visualized on CT and PET/CT
scans. Although our patients had relatively short follow-
up periods of 13 and 11 months, respectively, both
underwent successful curative resection.
Conclusions
Both of our cases are valuable to report. The manage-
ment of adrenal metastases from gastric cancer can pose
a dilemma for clinicians. This report shows that the
surgical treatment of adrenal metastasis from gastric
cancer is an option that may prolong survival in selected
patients, such as those with completely resectable lesions
or those with late metachronous metastases, as in our
patients. The clinical courses outlined herein support
the feasibility of selective surgical resection for adrenal
metastases in patients with gastric cancer.
Consent
Written informed consent was obtained from the patient
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Abbreviations
CT: Computed tomography; PET-CT: Positron emission tomography–computed
tomography.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DJK wrote the manuscript. JHL provided clinical opinions and the
histopathologic images. WK revised the manuscript. All authors read and
approved the final manuscript.
Author details
1Department of Surgery, Yeouido St Mary’s Hospital, The Catholic University
of Korea, 62 Yeouido-dong, Yeongdeungpo-gu, Seoul 150-713, Korea.
2Department of Surgery, Bucheon St Mary’s Hospital, College of Medicine,
The Catholic University of Korea, 62 Yeouido-dong, Yeongdeungpo-gu, Seoul
150-713, Korea.
Kim et al. World Journal of Surgical Oncology 2014, 12:116 Page 5 of 5
http://www.wjso.com/content/12/1/116Received: 2 September 2013 Accepted: 4 April 2014
Published: 24 April 2014
References
1. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS: Recurrence following curative
resection for gastric carcinoma. Br J Surg 2000, 87:236–242.
2. Lehnert T, Rudek B, Buhl K, Golling M: Surgical therapy for loco-regional
recurrence and distant metastasis of gastric cancer. Eur J Surg Oncol 2002,
28:455–461.
3. Cedermark BJ, Blumenson LE, Pickren JW, Elias EG: The significance of
metastases to the adrenal gland from carcinoma of the stomach and
esophagus. Surg Gynecol Obstet 1977, 145:41–48.
4. Lam KY, Lo CY: Metastatic tumours of the adrenal glands: a 30-year
experience in a teaching hospital. Clin Endocrinol (Oxf ) 2002, 56:95–101.
5. Do YR, Song HS, Kim IH: Adrenalectomy for metastatic disease to the
adrenal gland from gastric cancer: report of a case. Korean J Intern Med
2007, 22:18–20.
6. Sobin LH, Gospodarowicz MK: Wittekind (Eds): The TNM Classification of
Malignant Tumours. 6th edition. Geneva: International Union against Cancer;
2002.
7. Paul CA, Virgo KS, Wade TP, Audisio RA, Johnson FE: Adrenalectomy for
isolated adrenal metastases from non-adrenal cancer. Int J Oncol 2000,
17:181–187.
8. Lenert JT, Barnett CC Jr, Kudelka AP, Sellin RV, Gagel RF, Prieto VG, Skibber JM,
Ross MI, Pisters PW, Curley SA, Evans DB, Lee JE: Evaluation and surgical
resection of adrenal masses in patients with a history of extra-adrenal
malignancy. Surgery 2001, 130:1060–1067.
9. Abrams HL, Spiro R, Goldstein N: Metastases in carcinoma: analysis of
1000 autopsied cases. Cancer 1950, 3:74–85.
10. Sahagian-Edwards A, Holland JF: Metastatic carcinoma to the adrenal
glands with cortical hypofunction. Cancer 1954, 7:1242–1245.
11. Kapella M, Genet D, Pech De Laclause B, Durand-Fontanier S, Lachachi M,
Fabre A, Valleix D, Descottes B: [Adrenal metastasis: survival following
surgical resection] [in French]. J Chir (Paris) 2008, 145:346–349.
12. Kim SH, Brennan MF, Russo P, Burt ME, Coit DG: The role of surgery in the
treatment of clinically isolated adrenal metastasis. Cancer 1998,
82:389–394.
13. Wade TP, Longo WE, Virgo KS, Johnson FE: A comparison of
adrenalectomy with other resections for metastatic cancers. Am J Surg
1998, 175:183–186.
14. Lo CY, van Heerden JA, Soreide JA, Grant CS, Thompson GB, Lloyd RV,
Harmsen WS: Adrenalectomy for metastatic disease to the adrenal
glands. Br J Surg 1996, 83:528–531.
15. Kosaka T, Ueshige N, Sugaya J, Nakano Y, Tomita F, Saito H, Kita I, Takashima S:
A long surviving case of resected gastric cancer presenting with a
synchronous adrenal metastasis. Gastric Cancer 1999, 2:142–144.
16. Mokuno Y, Katayama M, Ogura Y, Kimura K, Koh K: Long-term survival after
resection of metachronous bilateral adrenal metastases of mucinous
gastric carcinoma: report of a case. Surg Today 2006, 36:554–558.
doi:10.1186/1477-7819-12-116
Cite this article as: Kim et al.: Surgical treatment for late-appearing
adrenal metastasis from gastric cancer: report of two cases. World
Journal of Surgical Oncology 2014 12:116.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
